Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]
News [5284]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Novel PET tracers and their future use in assessment of response to treatment
Dr Andrei Iagaru – Stanford University, CA, USA
Novel PET tracers and their future use in assessment of response to treatment ( Dr Andrei Iagaru – Stanford University, CA, USA )
17 Jun 2012
Clinical trials for rare tumour types
Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA
Clinical trials for rare tumour types ( Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA )
15 Jun 2012
Regorafenib effective for GISTs that progress due to resistance to approved...
Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA )
13 Jun 2012
ASCO 2012: Advances in myeloma
Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof...
ASCO 2012: Advances in myeloma ( Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Gareth Morgan - Royal Marsden Hospital, UK )
12 Jun 2012
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with...
Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada...
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )
12 Jun 2012
President's overview of ASCO 2012
Dr Michael Link - Stanford School of Medicine, California, USA
President's overview of ASCO 2012 ( Dr Michael Link - Stanford School of Medicine, California, USA )
4 Jun 2012
Afatinib delays progression of advanced lung adenocarcinomas
Dr James Yang - National Taiwan University Hospital, Taipei
Afatinib delays progression of advanced lung adenocarcinomas ( Dr James Yang - National Taiwan University Hospital, Taipei )
4 Jun 2012
Costly drugs versus paclitaxel as first line therapy for locally advanced or...
Dr Hope Rugo - University of California San Francisco, USA
Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, USA )
4 Jun 2012
Regorafenib effective for GISTs that progress due to resistance to approved...
Dr George Demetri - Dana Farber Cancer Institute, Boston, USA
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana Farber Cancer Institute, Boston, USA )
4 Jun 2012
Increased progression-free survival in advanced lung cancer with afatinib
Dr James Yang - National Taiwan University Hospital Taipei, Taiwan
Increased progression-free survival in advanced lung cancer with afatinib ( Dr James Yang - National Taiwan University Hospital Taipei, Taiwan )
3 Jun 2012
Current treatment practices in metastatic castration resistant prostate cancer
Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo...
Current treatment practices in metastatic castration resistant prostate cancer ( Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo Berruti )
22 May 2012
Prognostic biomarkers and next generation genomic sequencing
Prof Stefan Pfister – Cancer Research Centre, Heidelberg, Germany
Prognostic biomarkers and next generation genomic sequencing ( Prof Stefan Pfister – Cancer Research Centre, Heidelberg, Germany )
21 May 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation